The U.S. Food and Drug Administration (FDA) grants pediatric exclusivity for certain drugs when manufacturers agree to conduct studies in children. This exclusivity extends the market exclusivity period by six months [1].
What Drugs Received FDA Pediatric Exclusivity in 2024?
As of [current date], specific approvals granting pediatric exclusivity in 2024 have not been publicly detailed or compiled in a readily accessible list from the FDA. Information regarding these approvals is typically made public as they are granted or through company announcements and regulatory filings.
How Does Pediatric Exclusivity Work?
Pediatric exclusivity is a provision under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). When a sponsor completes a new clinical study or studies in pediatric populations outlined in a Written Request from the FDA, they may receive an additional six months of exclusivity on top of existing patent or other exclusivities [2]. This incentive encourages pharmaceutical companies to study their drugs in children, a population often underrepresented in clinical trials.
When Does Pediatric Exclusivity Typically Expire?
The six-month period of pediatric exclusivity begins at the expiration of the drug's existing patent or other market exclusivity. This means the drug's total protected market period is extended by six months [2]. For example, if a drug's patent was set to expire on January 1, 2024, and it received pediatric exclusivity, its effective market exclusivity would extend to July 1, 2024.
What is the Difference Between Pediatric Exclusivity and Pediatric Investigational New Drug (IND) Application?
Pediatric exclusivity is a market incentive granted after certain pediatric studies are completed and approved by the FDA. A Pediatric Investigational New Drug (IND) application is a regulatory submission that details the plan for conducting clinical trials in pediatric populations. Companies must file a Pediatric IND or amend an existing one to outline their proposed pediatric studies before seeking approval for these studies [3].
What are the Requirements for Granting Pediatric Exclusivity?
To receive pediatric exclusivity, a drug manufacturer must conduct studies in pediatric populations as requested by the FDA. These studies must be conducted according to an FDA "Written Request" and must yield scientifically valid data that may be relevant to the drug's use in children. Once the studies are completed and the data is submitted and accepted by the FDA, the six-month exclusivity is granted [2].
Where Can I Find a List of Drugs with Pediatric Exclusivity?
Information on specific drugs that have received pediatric exclusivity is generally found in FDA drug approval databases, company press releases, and through specialized pharmaceutical information services. DrugPatentWatch.com tracks patent and exclusivity information for pharmaceuticals, which can include details on pediatric exclusivity as it relates to market exclusivity timelines [4].
What are the Benefits of Pediatric Exclusivity for Drug Development?
The primary benefit of pediatric exclusivity is encouraging the development of safe and effective treatments for children. By providing an extended period of market protection, it offsets some of the costs and risks associated with conducting pediatric clinical trials, which can be complex and challenging. This leads to better-informed prescribing for younger patients and access to drugs that have been specifically studied for their use in pediatric populations [2].
What are the Potential Downsides or Criticisms of Pediatric Exclusivity?
While intended to benefit children, the pediatric exclusivity program has faced some criticism. Concerns have been raised about whether the requested studies always yield significant clinical benefits for children or if some requests are for studies that would have been conducted anyway for regulatory approval in adults. Additionally, the extension of market exclusivity can delay the availability of lower-cost generic or biosimilar versions of medications [5].
How Does FDA Pediatric Exclusivity Compare to Other Exclusivity Types?
The FDA grants several types of market exclusivity, each with different criteria and durations. These include:
* New Chemical Entity (NCE) exclusivity: Typically five years for a new drug.
* Orphan Drug exclusivity: Seven years for drugs treating rare diseases.
* Patent challenges: Exclusivity can be extended through patent litigation.
* Pediatric exclusivity: Six months, added to other existing exclusivities [1][2].
Pediatric exclusivity is unique in that it is directly linked to the completion of specific pediatric studies requested by the FDA, acting as an add-on to other forms of protection.
What are the Next Steps After Pediatric Exclusivity is Granted?
Once pediatric exclusivity is granted and added to a drug's existing patent or exclusivity period, the drug remains protected from generic competition until the combined exclusivity period expires. Following the expiration of all market protections, generic manufacturers can apply for FDA approval to market their versions of the drug, typically leading to lower prices [5].
Sources:
[1] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cderr/types-exclusivity
[2] https://www.fda.gov/children/childrens-health-and-safety/pediatric-exclusivity
[3] https://www.fda.gov/drugs/development-approval-process-drugs/pediatric-investigational-new-drug-application
[4] https://drugpatentwatch.com/
[5] https://www.brookings.edu/research/the-pediatric-exclusivity-program-a-costly-benefit-for-childrens-health/